All News

cardiac2.jpg (keep)

Pericarditis Management

d Eric Dein, MD

On the final day of ACR 2023 State of the Art Conference, Dr. Paul Cremer reviewed pericarditis management. Dr. Cremer, a cardiologist at the Cleveland Clinic Foundation, reviewed the questions patients ask about pericarditis including why the disease develops, will it recur, how is it treated, and what will their treatment duration be. 

Read Article
brain headache neuro

Treatment and Management of Neuropsychiatric Lupus

d Eric Dein, MD

On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 

Read Article
ACRmtg.jpg (keep)

ACR 2023 Convergence Brings Back the Poster Hall and 4 Day Meeting

d ACR

ACR Convergence 2023, the annual meeting of the American College of Rheumatology (ACR) and the world’s premier rheumatology experience, will be held Nov. 10 – 15 at the San Diego Convention Center in San Diego, CA.

Read Article
question-mark-1872634_640.jpg

ICYMI: What to do about pre-clinical RA?

d Robert Chao, MD

RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, especially what to do regarding pre-clinical RA.

Dr. Kevin Deane started the discussion by mapping out a very complex course of RA, beginning with a person’s genetic and environmental risk factors. What are Dr. Deane’s recommendations for management of pre-RA patients?

Read Article
pneumocystis,PJP

PJP Prophylaxis Needed with Steroids and Rituximab

d Jack Cush, MD

Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening infection in immunocompromised patients. The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving rituximab (RTX).

Read Article
Korean retrospective claims analysis of #RA (n=54 .7K; 39K RF/CCP+) (2010-2019; F/U 4.3 yrs) saw Parkinsons dx in 290 RA; Compared to controls, RA had a significant 1.74-fold higher risk of PD (found in seropos HR 1.95) but not seroneg RA https://t.co/GRahCXDuYt https://t.co/ohWK51frFr

Links:

Dr. John Cush RheumNow ( View Tweet)
Treatment with MTX in early CCP+ RA thought to be effective in slowing disease however StopRA study did not show a difference between HCQ and PBO in patients. We need to know more about HCQ vs MTX in this space! #RNL2023 https://t.co/hkypaEwZ8F cc: @uptoTate https://t.co/hgZNyU8YwU

Links:

Dr. John Cush RheumNow ( View Tweet)
STOP-RA study on HCQ preventing RA... HCQ did NOT prevent RA development in pre-RA pts @RheumNow #RNL2023 https://t.co/h1YicTORuw https://t.co/JRIFJzMudO

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/YrA7tXMKoI Cc: @ericdeinmd https://t.co/oXoeZYW7rU

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 Kevin Deane: natural history of RA The onset of RA is a spectrum of disease from genetic/environmental risks; local & systemic autoimmunity (ACPA/RF, mucosal factors); subclinical; unclassified arthralgias; classified RA When to start treatment? https://t.co/LEsPVQe9QW https://t.co/MbNmxZ39HO

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study of Calif. Hosp. records on women with SLE (n 2874) and RA (2309) found that Black, Hispanic, and Asian women had 1.3 - 1.5 fold more preterm births than Whites; & blacks had 2-2.4 more PTB than Asian, Hispanic, or Whites. https://t.co/7Nr5KJUNRc https://t.co/3fzTMiM4DG

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish study looked at risk of PsA in psoriasis pts showing PsA risk was significantly higher w/ worsening psoriasis. Incidence of PsA was 1.48/100PY, 3.00, and 5.49/100PY w/ mild, moderate and severe psoriasis. PsA risk was 3.2X higher w/ severe PSO https://t.co/H8QbkRp4d9 https://t.co/Hqlcf3f2bI

Links:

Dr. John Cush RheumNow ( View Tweet)
Pharma marketing payments to MDs (none; < $100; >$100) correlated with Medicare billing of Intraarticular Hyaluronic Acid injx. In 20 501 MDs, 41.5% gave HA injx; Odds incr w/ payment <$100 (OR 2.06) or >$100 (OR 3.28); 12.7% & 21% more likely https://t.co/BP395xm0TW https://t.co/MDxT8Kl4kq

Links:

Dr. John Cush RheumNow ( View Tweet)
Observational study of cannabis use in 25 cancer pts (52% w/ colon/lung/breast CA) taking a 2-wks of ad libitum cannabis noted to have improvements in pain intensity, pain interference, sleep quality, & cognitive function,but no change in quality of life. https://t.co/iZjGMM1Pud https://t.co/vkOWVqfCYi

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumThoughts: An Opportunity to Say Yes Hi, I am Dr. Kathryn Dao ( @KDAO2011 ) a rheumatologist and senior editor for the RheumNow Women in Rheumatology Campaign. I wanted to share you with an opportunity. An Opportunity to Say Yes. https://t.co/dJKWFAASV9 https://t.co/Cm4vn563Pz

Links:

Dr. John Cush RheumNow ( View Tweet)
Romania to U.S.: My Journey to a Permanent Residency One in four practicing physicians in the United States are international medical graduates. I am one of them. Dr. Maria Danila shares her IMG experience. https://t.co/vpxyosojxc https://t.co/FrIuLyvgXS

Links:

Dr. John Cush RheumNow ( View Tweet)
Another review on the annual salaries of different specialists.... https://t.co/bkkcIR5pa5

Links:

Dr. John Cush RheumNow ( View Tweet)

Full Read comprehensive revie by Isenberg on what Rx work in SLE; they review RCT data on approved drugs and Rx in development: - Obinutuzumab - Dapirolizumab - Deucravacitinib - Litifilimab - Atacicept - Telitacicept https://t.co/jMLlRZuK6e https://t.co/8K0dYLieAH

Links:

Dr. John Cush RheumNow ( View Tweet)
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us this Tuesday for our the start of our May Tuesday Night Rheumatology focusing on Rheumatoid Arthritis: Revolutionary Advances in Therapy https://t.co/TbNYaGJ3sk https://t.co/DiJwjvUX1d

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×